A Good Reminder: Most Drugs Won’t Make the Cut
Recap - We count at least nine failures of one sort or another (Complete Response Letters, failed trials) in the last five days from companies such as Pozen (POZN), … Continue Reading
Read nowSearch Results for gene therapy
The Market Just Isn’t Convinced the AVEO Nightmare is Over
Insights - AVEO has lost more than 90% of its market valuation in the last 21 months; another of PropThink’s “Drugs that Disappointed in 2013.” In February, AVEO … Continue Reading
Read nowRecap: A Mixed Bag in Biopharma Earnings
Recap - An update from Sarepta Therapeutics (SRPT) first thing on Monday morning caught the attention of the biotech world – and sent one of our 2014 recommendations to PropThink Premium … Continue Reading
Read now
Drugs that Disappointed Investors in 2013: Infinity’s IPI-145
Insights - A look at what caused Infinity Pharma's (INFI) spectacular rise and fall in 2013, and the road ahead.
Read now
FDA-Approved Drugs That Disappointed in 2013: Ariad’s Iclusig
Insights - First up, Ariad Pharmaceuticals’ (ARIA) Iclusig. ARIA has regained almost 50%, or $932 million, in lost market value since U.S. regulators announced the resumption in marketing … Continue Reading
Read now
Agios, of 2013 IPO Class, Impresses With Early Oncology Asset
Insights - Agios Pharmaceuticals (AGIO) soared in trading on Monday after reporting Phase 1 data demonstrating that its cancer metabolism drug AG-221, a first-in-class inhibitor of IDH2 … Continue Reading
Read nowThis ETF Broke a Major Trendline Today: What’s Next?
Recap - Continued weakness in the healthcare sector this week was marked on Friday by the iShares Biotech Index’s (IBB) break of a key uptrend and support level, suggesting … Continue Reading
Read now